Azithromycin-induced proarrhythmia and cardiovascular death

Area of Science:

• Pharmacology
• Cardiology
• Clinical Research

Background:

• Azithromycin is a widely prescribed macrolide antibiotic.
• Concerns exist regarding its potential cardiovascular risks, including QT interval prolongation.

Purpose of the Study:

• To review the association between azithromycin use and increased cardiovascular risk.
• To identify patient populations at higher risk for adverse cardiac events.

Main Methods:

• Comprehensive literature search of MEDLINE and citation reviews.
• Inclusion of English-language observational studies and case reports.
• Evaluation of studies assessing azithromycin's link to QT prolongation and cardiovascular events.

Main Results:

• Six case reports suggested a possible link between azithromycin and QT prolongation, with three reporting proarrhythmic events.
• A prospective study showed insignificant QTc prolongation in low-risk individuals.
• A large cohort study indicated a slight increase in cardiovascular deaths, particularly in high-risk patients; another cohort study found no association.

Conclusions:

• Emerging evidence suggests azithromycin can prolong the QT interval and, rarely, cause torsade de pointes.
• Patients with risk factors (e.g., female, elderly, pre-existing CVD, hypokalemia, bradycardia, concurrent QT-prolonging drugs) face the highest risk.
• Azithromycin appears relatively safe for patients without these additional risk factors.